Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, announces today that it has reached an
agreement with the management of DSM Deretil on a management buy-out. DSM
Deretil is a business unit of DSM Anti-Infectives. Financial details will not
be disclosed.
This divestment fits in the strategic review of DSM Anti-Infectives as
announced in June 2007. DSM believes the greatest value will be generated
through a partnering strategy combined with innovation initiatives and
restructuring measures. The review opened possibilities for divestments of
separate businesses, such as DSM Deretil.
Jan Zuidam,
Deputy Chairman of the Managing Board of Directors of Royal DSM said: “
This transaction gives better chances for DSM Anti-Infectives to fully focus
on its core future activity as a leading player in generic API’s, and for
Deretil to focus on the specific dynamics of the side chain business. This is
a good move for both parties, and we are convinced this will in the near
future turn out a win for all involved.”
Deretil will completely focus on its core business: the marketing, sales and
manufacturing of side-chains for the production of Active Pharmaceutical
Ingredients (API’s). Lluis Franquesa, president of Deretil: “We
are proud that DSM has put the trust in us to take over full responsibility
and ownership of Deretil. We as management team of Deretil are fully aware of
our responsibilities towards, our people, our customers and the society in
which we operate, and are fully prepared to take this responsibility. We will
continue as planned the previously announced restructuring of the
manufacturing base, involving the closure of one of the plants on the
Villaricos site in Spain and moving the production from that plant to China
.”
There is no significant impact on the employees of Deretil expected as direct
consequence of this management buy-out. The effect of the sale of DSM Deretil
on DSM’s total net sales will be approximately EUR 35 million. The book result
of the transaction is, on balance, not expected to be material.
DSM Anti-Infectives
DSM Anti-Infectives is the world's leading
supplier of active pharmaceutical ingredients such as amoxicillin, ampicillin,
cephalexin and cefadroxil, the worlds most widely used broad spectrum
antibiotics for combating bacterial infections. Its product portfolio also
includes nystatin, penicillin, penicillin intermediates (6-APA and 7-ADCA) and
industrial enzymes. The company is headquartered in Delft, the Netherlands,
and has a global presence with manufacturing facilities in Europe, Africa,
China and India and sales offices across the globe. More information can be
found on
http://www.dsm.com/en_US/html/dai/daihomepage.htm.
DSM Deretil
DSM Deretil is part of Royal DSM N.V., through its
business group DSM Anti-Infectives. DSM Deretil’s core production plant is in
Villaricos, Spain, and Deretil runs another facility in China. The main
offices are in Barcelona with an extensive commercial network in Europe,
America and Asia, with over 400 employees. DSM Deretil’s safety, health and
environment program complies with the most demanding international standards
and has the highest priority for the management and its employees. DSM Deretil
adheres to the Responsible Care Program. The world’s leading antibiotics are
all manufactured from the raw materials produced by Deretil. More information
can be found on
http://www.dsm.com/en_US/html/deretil/Deretil_Home.htm.
